E. Goode

590 total citations
12 papers, 325 citations indexed

About

E. Goode is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, E. Goode has authored 12 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 4 papers in Surgery and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in E. Goode's work include Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). E. Goode is often cited by papers focused on Colorectal Cancer Treatments and Studies (3 papers), Gastric Cancer Management and Outcomes (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). E. Goode collaborates with scholars based in United Kingdom and United States. E. Goode's co-authors include Pascal Meier, Arnaud J. Legrand, Maria Konstantinou, Elizabeth Smyth, Sheela Rao, Ian Chau, Naureen Starling, Clare Peckitt, David Cunningham and David Watkins and has published in prestigious journals such as Journal of Clinical Oncology, Molecular Cell and Annals of Oncology.

In The Last Decade

E. Goode

11 papers receiving 321 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
E. Goode United Kingdom	7	177	108	106	86	51	12	325
He Du China	9	86 0.5×	186 1.7×	79 0.7×	61 0.7×	22 0.4×	26	323
Kelvin Shenq Woei Siew Malaysia	5	206 1.2×	156 1.4×	87 0.8×	63 0.7×	41 0.8×	9	410
Yuki Matsubara Japan	9	87 0.5×	77 0.7×	74 0.7×	16 0.2×	69 1.4×	56	289
Takako Suda Japan	11	136 0.8×	117 1.1×	70 0.7×	140 1.6×	106 2.1×	25	391
Xianfa Wang China	9	259 1.5×	53 0.5×	188 1.8×	65 0.8×	103 2.0×	13	385
Judith M. Versluis Netherlands	10	338 1.9×	102 0.9×	70 0.7×	158 1.8×	68 1.3×	43	408
Julie Price Hiller Canada	5	227 1.3×	82 0.8×	68 0.6×	105 1.2×	68 1.3×	9	324
Byung Soo Kim South Korea	10	164 0.9×	177 1.6×	40 0.4×	100 1.2×	33 0.6×	24	413
R Canaletti Italy	6	171 1.0×	106 1.0×	63 0.6×	51 0.6×	51 1.0×	7	309
Marc Puigvehí Spain	11	120 0.7×	35 0.3×	60 0.6×	44 0.5×	94 1.8×	24	515

Countries citing papers authored by E. Goode

Since Specialization

Citations

This map shows the geographic impact of E. Goode's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Goode with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Goode more than expected).

Fields of papers citing papers by E. Goode

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Goode. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Goode. The network helps show where E. Goode may publish in the future.

Co-authorship network of co-authors of E. Goode

This figure shows the co-authorship network connecting the top 25 collaborators of E. Goode. A scholar is included among the top collaborators of E. Goode based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Goode. E. Goode is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Goode, E., Evanthia T. Roussos Torres, & Sheeba Irshad. (2021). Lymph Node Immune Profiles as Predictive Biomarkers for Immune Checkpoint Inhibitor Response. Frontiers in Molecular Biosciences. 8. 674558–674558. 16 indexed citations

Battisti, Nicolò Matteo Luca, María Sol Andrés, Karla A. Lee, et al.. (2021). Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer. Breast Cancer Research and Treatment. 188(1). 149–163. 45 indexed citations

Goode, E., Danielle Crawley, Charlotte Moss, et al.. (2020). 243P UK experience of the management of pregnancy associated breast cancer: A national retrospective review of practice. Annals of Oncology. 31. S337–S337.

Battisti, Nicolò Matteo Luca, Vasileios Angelis, E. Goode, et al.. (2020). 222P Rates of cardiac adverse events in older versus younger adults receiving trastuzumab for HER2-positive early breast cancer: Results from 931 patients treated at The Royal Marsden. Annals of Oncology. 31. S330–S330. 2 indexed citations

Legrand, Arnaud J., Maria Konstantinou, E. Goode, & Pascal Meier. (2019). The Diversification of Cell Death and Immunity: Memento Mori. Molecular Cell. 76(2). 232–242. 126 indexed citations

Davidson, Michael, E. Goode, Kyriakos Kouvelakis, et al.. (2018). Survival in Advanced Esophagogastric Adenocarcinoma Improves With Use of Multiple Lines of Therapy: Results From an Analysis of More Than 500 Patients. Clinical Colorectal Cancer. 17(3). 223–230. 26 indexed citations

Goode, E., Francesco Sclafani, Joo Ern Ang, et al.. (2017). Treatment and Survival Outcome of BRAF-Mutated Metastatic Colorectal Cancer: A Retrospective Matched Case-Control Study. Clinical Colorectal Cancer. 17(1). e69–e76. 46 indexed citations

Davidson, Michael, E. Goode, D.J. Hughes, et al.. (2017). Survival in advanced oesophagogastric adenocarcinoma (OGA) improves with the use of multiple lines of therapy: Results from an analysis of over 500 patients (pts). Annals of Oncology. 28. v219–v219. 4 indexed citations

Goode, E. & Elizabeth Smyth. (2016). Immunotherapy for Gastroesophageal Cancer. Journal of Clinical Medicine. 5(10). 84–84. 39 indexed citations

10.

Goode, E., Joo Ern Ang, David González de Castro, et al.. (2016). Outcomes of patients (pts) with BRAF mutated (BRAF MT) Colorectal Cancer (CRC): The Royal Marsden Experience.. Journal of Clinical Oncology. 34(4_suppl). 644–644. 1 indexed citations

11.

Spain, Lavinia, et al.. (2016). The combination of vemurafenib and cobimetinib in advanced melanoma. Expert Opinion on Orphan Drugs. 4(11). 1105–1111. 3 indexed citations

12.

Yousaf, Nadia, et al.. (2015). The cost of ipilimumab toxicity. Melanoma Research. 25(3). 259–264. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact